PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 50,15 | 50,15 | 2023-11-07 |
| Vict Th Engwalls Stiftelse | 1,79 | 1,79 | 2023-09-27 |
| Avanza Pension | 1,63 | 1,63 | 2023-09-27 |
| Henrik Skog | 1,14 | 1,14 | 2023-09-27 |
| Arne Arvidsson | 1,10 | 1,10 | 2023-09-27 |
| Nordnet Pensionsförsäkring | 0,94 | 0,94 | 2023-09-27 |
| Staffan Engelbert Bodén | 0,65 | 0,65 | 2023-09-27 |
| Arne Skogvall | 0,61 | 0,61 | 2023-09-27 |
| Tommy Johansson | 0,55 | 0,55 | 2023-09-27 |
| Torsten Ingemar Jonsson | 0,55 | 0,55 | 2023-09-27 |
2024-02-15 Bokslutskommuniké 2023